1. Home
  2. MSN vs CALC Comparison

MSN vs CALC Comparison

Compare MSN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Emerson Radio Corporation

MSN

Emerson Radio Corporation

HOLD

Current Price

$0.38

Market Cap

8.4M

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.77

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSN
CALC
Founded
1948
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4M
9.7M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
MSN
CALC
Price
$0.38
$0.77
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
112.6K
290.9K
Earning Date
02-17-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.30
Revenue
$77,829,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.52
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$0.46
52 Week High
$0.85
$7.20

Technical Indicators

Market Signals
Indicator
MSN
CALC
Relative Strength Index (RSI) 41.08 47.16
Support Level $0.36 $0.52
Resistance Level $0.41 $0.93
Average True Range (ATR) 0.03 0.11
MACD -0.00 -0.02
Stochastic Oscillator 23.80 6.90

Price Performance

Historical Comparison
MSN
CALC

About MSN Emerson Radio Corporation

Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: